Effect of hydrophilic and hydrophobic polymers on release kinetics of metoprolol succinate extended release tablets
Main Article Content
Abstract
subjected to in vitro drug release studies. The formulations containing methocel 10000 Cps, Eudragit® L100 showed good release retardation. All the prepared formulations showed first-order release kinetics with matrix diffusion mechanism of release. The formulation containing 52.06% w/w of methocel 10000 Cps, 8.75% Eudragit® L100 offered the required release rate according to USP Pharmacopoeial guidelines. The combination of hydrophilic and hydrophobic polymers can effectively control the drug release for freely water-soluble drugs in case of extended release formulations which are the
upcoming dosage forms for patient compliance in all aspects.
Downloads
Article Details
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
References
Chien YW. Novel drug delivery systems. New York: Marcel Dekker Inc;
2nd ed. p. 1-15.
Hendrickson R, Remington. The science and practice of pharmacy. Vol.1,
st ed. Philadelphia: Lippincott Williams and Wilkins. Hong Kong:
published by Wolters Kluwer Health Pvt. Ltd; 2007. p. 917.
Tripathi KD. Essentials of medical pharmacology. 6th ed.(New Delhi):
Jyapee brother’s medical publishers (p) Ltd; 2005 p. 528.
Roni MA, Kibria G, Jalil R. Formulation and in vitro evaluation of alfuzosin extended release tablets using directly compressible Eudragit®. Indian J Pharm Sci 2009;71:p.252-258.
Nair A, Gupta R, Vasanti S. In vitro controlled release of Alfuzosin
hydrochloride using HPMC-based matrix tablets and its comparison
with marketed product. Pharm Dev Technol 2007;12:p.621-625.
Gohel MC, Patel TP, Bariya SH. Studies in preparation and evaluation
of pH-independent sustained-release matrix tablets of verapamil Hcl
using directly compressible Eudragits®. Pharm Dev Technol 2003;
:323-33.
Takka S, Rajbhandari S, Sakr A. Effect of anionic polymers on the
release of propranolol hydrochloride from matrix tablets. Eur J Pharm
Biopharm 2001;52:75-82.
Aulton ME. Pharmaceutics, the science of dosage form design. Oxford:
Churchill Livingstone; 2005. p. 133-4.
The United States Pharmacopoeia.USP27/ NF22. The Official Compendia
of Standards, Asian Edition. (publisher name& Corporate author
–The United State Pharmacopoeial convention)The United State
Pharmacopeial Convention. Rockville: 2004. p. 1280.
Dissolution methods for drug products, US FDA. Available from: http://
www.accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults_
Dissolutions.cfm?PrintAll=1 [Last accessed on 2011 Apr 26].
Bravo SA, Lamas MC, Salamón CJ. In vitro studies of diclofenac sodium
controlled-release from biopolymer hydrophilic matrices. J Pharm
Pharm Sci 2002;5:213-9.
Al-Taani BM, Tashtoush BM. Effect of microenvironment pH of swellable
and erodable buffered matrices on the release characteristics of
diclofenac Sodium. AAPS PharmSciTech 2003;4:E43.
Colombo P. Swelling-controlled release in hydrogel matrices for oral
route. Adv Drug Deliv Rev 1993;11:37-57.
Ritger PL, Peppas NS. A simple equation for description of solute release
II: Fickian and anomalous release from swellable devices. J Control
Release 1987;5:37-42.
Siepmann J, Peppas NA. Modeling of drug release from delivery systems
based on hydroxy propyl methylcellulose (HPMC). Adv Drug Deliv Rev
;48:139-57.